Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Transducer Mechanism: Nuclear Receptors01:31

Transducer Mechanism: Nuclear Receptors

2.0K
Nuclear receptors, or NRs, are unique transcription factors that regulate gene transcription and affect the cellular pathways involved in reproduction, development, or metabolism. Their ability to be stimulated by small lipophilic ligands and control vital cellular processes makes them ideal drug targets. Nearly 10-15% of currently prescribed drugs target these receptors.
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
2.0K
Cell Specific Gene Expression01:58

Cell Specific Gene Expression

14.6K
Multicellular organisms contain a variety of structurally and functionally distinct cell types, but the DNA in all the cells originated from the same parent cells. The differences in the cells can be attributed to the differential gene expression. Liver cells, whose functions include detoxification of blood, production of bile to metabolize fats, and synthesis of proteins essential for metabolism, must express a specific set of genes to perform their functions. Gene expression also varies with...
14.6K
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

539
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
539
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

3.4K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
3.4K
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

102
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
102
Human Genetics01:28

Human Genetics

1.0K
Human genetics provides a profound framework for understanding the interplay between genetic predispositions and human psychology. At the heart of this discipline lies the study of how genes influence physical traits, behaviors, and susceptibility to diseases. Each person carries a unique genetic code that subtly or significantly shapes their psychological and behavioral landscape.
The complex relationship between genetics and psychology is observable through common biological components such...
1.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Correction: Comparison of intraocular pressure measured by Goldman applanation tonometer, noncontact tonometer and trans-palpebral tonometer.

BMC ophthalmology·2026
Same author

Crosstalk Between Immunometabolic Pathways in Non-Small Cell Lung Cancer.

Immunological investigations·2026
Same author

A quantum resistant chaos driven image encryption framework for secure visual data transmission in intelligent transportation systems.

Scientific reports·2026
Same author

Physiology Still Matters: Lessons From FAVOR III China.

Journal of the American College of Cardiology·2026
Same author

Hemodynamic improvement immediately following percutaneous recanalization of chronic total occlusions.

Cardiovascular revascularization medicine : including molecular interventions·2026
Same author

Physical activity and glycosylphosphatidylinositol-specific phospholipase D1 (GPLD1) plasma levels in different age cohorts.

PloS one·2026

Related Experiment Video

Updated: Nov 11, 2025

Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis NASH Resolution
04:14

Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis NASH Resolution

Published on: April 16, 2019

12.3K

Epigenetics in NAFLD/NASH: Targets and therapy.

Nalini Sodum1, Gautam Kumar1, Sree Lalitha Bojja1

  • 1Department of Pharmacology, Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education, Manipal 576104, Karnataka, India.

Pharmacological Research
|March 27, 2021
PubMed
Summary

Epigenetics offers new insights into non-alcoholic fatty liver disease (NAFLD) development. Targeting these epigenetic changes may lead to novel therapies for NAFLD, a growing global health concern.

Keywords:
3-deazaneplanocin A (PubChem CID: 73087)Berberine (PubChem CID: 2353)DNA methylationEzetimibe (PubChem CID: 150311)Gemfibrozil (PubChem CID: 3463)HDACHistone modificationLiraglutide (PubChem CID: 16134956)Metformin (PubChem CID: 4091)MicroRNAsNon-alcoholic fatty liver diseaseNon-alcoholic steatohepatitisResveratrol (PubChem CID: 445154)Rimonabant hydrochloride (PubChem CID: 104849)Sitagliptin (PubChem CID: 4369359)Vitamin E (PubChem CID: 14985)Vorinostat (PubChem CID: 5311)β-cryptoxanthin (PubChem CID: 5281235)

More Related Videos

Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis
08:58

Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis

Published on: March 11, 2017

16.4K
Novel In Vivo Micro-Computed Tomography Imaging Techniques for Assessing the Progression of Non-Alcoholic Fatty Liver Disease
08:41

Novel In Vivo Micro-Computed Tomography Imaging Techniques for Assessing the Progression of Non-Alcoholic Fatty Liver Disease

Published on: March 24, 2023

1.4K

Related Experiment Videos

Last Updated: Nov 11, 2025

Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis NASH Resolution
04:14

Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis NASH Resolution

Published on: April 16, 2019

12.3K
Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis
08:58

Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis

Published on: March 11, 2017

16.4K
Novel In Vivo Micro-Computed Tomography Imaging Techniques for Assessing the Progression of Non-Alcoholic Fatty Liver Disease
08:41

Novel In Vivo Micro-Computed Tomography Imaging Techniques for Assessing the Progression of Non-Alcoholic Fatty Liver Disease

Published on: March 24, 2023

1.4K

Area of Science:

  • Hepatology and Molecular Medicine
  • Metabolic Disorders Research

Background:

  • Non-alcoholic fatty liver disease (NAFLD) is a prevalent condition linked to metabolic syndrome, with limited therapeutic options.
  • Current management focuses on lifestyle changes and non-specific drugs, highlighting an unmet need for targeted treatments.

Purpose of the Study:

  • To explore the role of epigenetics in NAFLD pathogenesis.
  • To discuss the potential of epigenetic modifications as therapeutic targets for NAFLD.
  • To review how environmental factors influence NAFLD through epigenetic mechanisms.

Main Methods:

  • Literature review focusing on epigenetic mechanisms in NAFLD.
  • Analysis of existing research on environmental influences on NAFLD epigenetics.
  • Examination of drug mechanisms targeting epigenetic pathways in NAFLD.

Main Results:

  • Epigenetic modifications provide a mechanistic link between environmental factors, metabolic syndrome, and NAFLD development.
  • The plasticity of epigenetic changes offers opportunities for therapeutic intervention.
  • Several potential drugs may exert their effects through epigenetic modulation in NAFLD.

Conclusions:

  • Epigenetics represents a promising frontier for understanding and treating NAFLD.
  • Targeting epigenetic pathways could lead to novel preventative and therapeutic strategies for NAFLD.
  • Further research into drug-induced epigenetic modifications is warranted for NAFLD treatment.